Pathos AI, Inc. has closed $237 million in Series E financing, led by Bristol Myers Squibb, to scale their AI-driven drug development platform and advance their oncology pipeline.
PRIVATEOct 23, 2026
Amount Raised
$237 Million
Round Type
Series E
New YorkBiotechnologyArtificial IntelligenceMachine Learning
Investors
Bristol Myers Squibb
Description
Pathos AI, Inc., a clinical-stage AI and technology company, has successfully secured $237 million in a Series E financing round. This funding will help scale their Agentic AI drug development platform and advance their oncology pipeline. The post-money valuation of the company is approximately $3 billion. The financing was supported by existing investors and led by Bristol Myers Squibb.
Who to call at Pathos AI, and when
A new round usually means Pathos AI is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Pathos AI raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Pathos AI, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Pathos AI
Location
New York, New York, United States
About
Pathos AI, Inc. is a clinical-stage AI and technology company focused on advancing its own therapeutic pipeline of drugs. The company uses its proprietary AI platform, Foundry, to enhance drug development, particularly in oncology. Pathos AI aims to revolutionize the way drugs are developed through advanced artificial intelligence technologies. With substantial funding, the company is set to further scale its operations and pipeline.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pathos AI raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyArtificial IntelligenceMachine Learning